Cardiol Therapeutics Inc. CRDL
1.00 USD +0.07 (+7.39%)
At closeNov 6, 2026, 5:03 PM EST
1.00 +0.01 +0.50%
After hours · Nov 6, 5:03 PM ET
0.94 Day range 1.00
0.926 52-week range 2.29
- YTD
- +4.30%
- 1 year
- -2.45%
News
prnewswire.com Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC TORONTO, Nov. 3, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
benzinga.com Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis As of September 23, 2026, 110 patients have been enrolled in MAVERIC, achieving the Company's original recruitment target ahead of its end-of-September guidance."A blinded review of events in MAVERIC…
benzinga.com Cardiol Therapeutics Files $150M Base Shelf Prospectus, Enabling Future Offerings Of Shares, Debt, Warrants And Other Securities Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
benzinga.com Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10 Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.- benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
benzinga.com Cardiol Therapeutics Announces Publication Of Phase II MAvERIC Study Results In The Journal of the American Heart Association The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. The publication describes clinical findings in which CardiolRx™ was associated with rapid and sustained…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com Cardiol Advances Key Studies and Secures Funding to Push New Heart Treatments Forward Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
benzinga.com Cardiol Therapeutics Announces Publication Of Results From Phase II ARCHER Study In ESC Heart Failure, Journal Of European Society Of Cardiology Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic…
benzinga.com Cardiol Therapeutics Surpasses 50% Participant Enrollment In MAVERIC Phase III Study Of CardiolRx Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic…
benzinga.com Why MongoDB Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket - benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
benzinga.com Cardiol Therapeutics Announces New, Comprehensive Data From ARCHER, Randomized Double-Blind, Placebo-Controlled, Multi-Center Phase II Clinical Trial Of CardiolRx In Patients With Acute Myocarditis Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with…- benzinga.com Cardiol Therapeutics Q3 EPS $(0.09), Inline Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 30.77 percent increase over losses of $(0.13) per share from the…
- benzinga.com Cardiol Therapeutics Receives USPTO Notice Of Allowance For Patent On Cannabidiol Heart Therapies Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual…
- benzinga.com Cardiol Therapeutics To Present New Data From ARCHER Trial, Highlighting Magnitude Of Reduction In LV Mass And Read Through To Heart Failure, At Cardiology Conference In November MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the…
- benzinga.com Cardiol Therapeutics Completes $11M Private Placement Selling 11M Units At $1/Unit; Says MAVERIC Phase III Pivotal Trial Of Orphan Drug Candidate CardiolRx In Recurrent Pericarditis Is Fully Funded Through To A Planned NDA Submission With The FDA; Data From The ARCHER Trial To Be Presented At A Cardiology Conference In November 2025 MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the…
- benzinga.com Cardiol Therapeutics Reports Compelling ARCHER Trial Results Supporting Advancement of CardiolRx And CRD-38 in Myocarditis And Heart Failure Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.Reduction in ECV was associated with…
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 446 companies hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 200 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 78 companies made new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 528 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 404 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 402 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 198 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.
- benzinga.com 52 Biggest Movers From Yesterday Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.